Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (<i>FLT3</i>-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)Mark J. Levis, Kristy Burns, Jörge E. Cortes et al.|Blood|2024Cited by 5
QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)Harry P. Erba, Pau Montesinos, Elżbieta Patkowska et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 0